Document is current
Any future updates will be listed below
-
Authors
Hu, Lu https://orcid.org/0000-0002-1594-8828
Lin, Jinyu
Sun, Liping https://orcid.org/0000-0002-2420-8936
Berezuk, Alison M.
Tuttle, Katharine S.
Zhu, Xing
Seo, Hyuk-Soo https://orcid.org/0000-0003-0646-2102
Dhe-Paganon, Sirano https://orcid.org/0000-0003-0824-5929
Li, Pan
Sun, Yang
Ni, Lisheng
Zhang, Jianan
Tan, Dazhi
Wakimoto, Hiroaki https://orcid.org/0000-0001-8225-241X
Cahill, Daniel P.
Bai, Xiaochen https://orcid.org/0000-0002-4234-5686
Luo, Xuelian https://orcid.org/0000-0002-5058-4695
Asara, John M. https://orcid.org/0000-0001-7450-2589
Subramaniam, Sriram
Shan, Yibing https://orcid.org/0000-0002-3865-8110
-
Funding
Funding for this research was provided by:
Massachusetts General Hospital (ISF)
Massachusetts General Hospital (ECOR psotdoc fellowship)
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 11 December 2025
First Online: 13 January 2026
Change Date: 16 January 2026
Change Type: Update
Change Details: In the version of the article initially published, the author of ref. 30 was given as “Dixon, S. J.” but should have been “Kahlson, M. A. et al”. This correction has been made to the HTML and PDF versions of the article.
Competing interests
: L.H. and X.W. are inventors of a patent application covering chemical probes for chemoproteomic profiling. D.P.C. has received financial compensation from Lilly (2020), Boston Pharmaceuticals (2020), GlaxoSmithKline (2021), Pyramid Biosciences (equity interest 2021), the Massachusetts Institute of Technology (2022), Incephalo (2023), Servier (2023) and Boston Scientific (2023) for advisory input. D.P.C. has also received financial compensation and travel reimbursement from Merck for invited lectures (2016) and from the US National Institutes of Health and Department of Defense for clinical trial and grant review (2023). S.S. is the founder and chief executive officer of Gandeeva Therapeutics. X.W. has financial interest in Tasca Therapeutics, which is developing small-molecule modulators of TEAD palmitoylation and transcription factors. X.W.’s interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies. The other authors declare no competing interests.
